Rare diseases
Investigational molecules
Locations
A Phase 2a Study Evaluating the Efficacy and Safety of MK-8690 in Adults with Moderately to Severely Active Ulcerative Colitis
ItalySwitch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer
ItalyPhase I/II Study of AZD6621 Safety and Efficacy in Adult Men with Metastatic Prostate Cancer
ItalyStudy of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)
ItalyA Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)
ItalyStudy of ly4395089 and mirikizumab in adults with moderately to severely active Crohn’s disease
ItalySafety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)
ItalyPhase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo
ItalyPhase 1/2 Study of CR-001 Safety and Dose Finding in Adults with Locally Advanced or Metastatic Solid Tumors
ItalyEvaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A
ItalyA Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors
ItalyStudy of MK-1045 alone or with Tocilizumab in patients with Non‑Hodgkin Lymphoma to evaluate safety and efficacy
ItalyTell us about your condition – we search every trial in Europe and connect you with the right site.
